CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with 2318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients

Molecular Biology Reports

Volumn 38, Issue 8, 2011, Pages 5125-5132

  Duan, Shaoqiong ^a   Zhang, Guoyu ^a   Han, Qunying ^a   Li, Zhu ^a   Liu, Zhengwen ^a   Chen, Jinghong ^b   Lv, Yi ^a   Li, Na ^a   Wang, Yawen ^a   Li, Man ^a   Lou, Sai ^a   Yang, Mingbo ^a   Zhu, Qianqian ^a   Xing, Fanfan ^a  

^a First Affiliated Hospital   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Association; Chronic HBV infection; CTLA 4; Genetic polymorphism

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; THREONINE;

ARTICLE; CHINESE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 GENE; DNA SEQUENCE; EXON; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CTLA-4 ANTIGEN; ETHNIC GROUPS; EXONS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

HEPATITIS B VIRUS;

EID: 84855237235     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0660-7     Document Type: Article

References (42)

1. Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337:1733-1745 (Pubitemid 27527771)
2. Löhr HF, Krug S, Herr W et al (1998) Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver 18:405-413 (Pubitemid 28550325)
3. Heathcote J, McHutchison J, Lee S et al (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30:531-536 (Pubitemid 29357521)
4. Walunas TL, Lenschow DJ, Bakker CY et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
5. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465
6. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540 (Pubitemid 26192363)
7. Ueda H, Howson JM, Esposito L et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511 (Pubitemid 36648570)
8. Aguilar F, Torres B, Sánchez-Román J, Núñez- Roldán A, González-Escribano MF (2003) CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 64:936-940 (Pubitemid 37210844)
9. Parks CG, Hudson LL, Cooper GS et al (2004) CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. Lupus 13:784-791 (Pubitemid 39457440)
10. Bouqbis L, Izaabel H, Akhayat O et al (2003) Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun 4:132-137 (Pubitemid 38967587)
11. Agarwal K, Czaja AJ, Jones DE, Donaldson PT (2000) Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 31: 49-53 (Pubitemid 30033688)
12. Agarwal K, Jones DE, Daly AK et al (2000) CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 32:538-541 (Pubitemid 30180371)
13. Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F (2001) CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 62:1356-1362 (Pubitemid 33116973)
14. Fan LY, Tu XQ, Cheng QB et al (2004) Cytotoxic T lymphocyte associated antigen-4 gene polymorphisms confer susceptibility to primary biliary cirrhosis and autoimmune hepatitis in Chinese population. World J Gastroenterol 10:3056-3059
15. Thio CL, Mosbruger TL, Kaslow RA et al (2004) Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 78:11258-11262 (Pubitemid 39299664)
16. Mohammad Alizadeh AH, Hajilooi M, Ranjbar M, Fallahian F, Mousavi SM (2006) Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 12:630-635 (Pubitemid 43380797)
17. Schott E, Witt H, Pascu M et al (2007) Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 19:947-951 (Pubitemid 350287400)
18. Gu X, Qi P, Zhou F et al (2010) +49GA polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 71:83-87
19. Lee YJ, Lo FS, Shu SG et al (2001) The promoter region of the CTLA4 gene is associated with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 14:383-388
20. Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97-98 (Pubitemid 41653949)
21. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2:145-152 (Pubitemid 33674879)
22. Mäurer M, Loserth S, Kolb-Mäurer A et al (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54:1-8 (Pubitemid 34492947)
23. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165: 6606-6611
24. Slot MC, Sokolowska MG, Savelkouls KG, Janssen RG, Damoiseaux JG, Cohen Tervaert JW (2008) Immunoregulatory gene polymorphisms are associated with ANCA-related vasculi-tis. Clin Immunol 128:39-45
25. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-507 (Pubitemid 35477041)
26. Takahashi T, Tagami T, Yamazaki S et al (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-310
27. Jonson CO, Hedman M, Karlsson Faresjö M et al (2006) The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children. Clin Exp Immunol 145:48-55 (Pubitemid 43893932)
28. Xu D, Fu J, Jin L et al (2006) Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177:739-747 (Pubitemid 43939189)
29. Stoop JN, van der Molen RG, Baan CC et al (2005) Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41:771-778 (Pubitemid 40462939)
30. Jiang Z, Feng X, Zhang W et al (2007) Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. Liver Int 27:1202-1208 (Pubitemid 47543148)
31. Wang XB, Zhao X, Giscombe R, Lefvert AK (2002) A CTLA-4 gene polymorphism at position-318 in the promoter region affects the expression of protein. Genes Immun 3:233-234 (Pubitemid 38961137)
32. Chistiakov DA, Savost'anov KV, Turakulov RI, Efremov IA, Demurov LM (2006) Genetic analysis and functional evaluation of the C/T(-318) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. Clin Immunol 118:233-242 (Pubitemid 43204318)
33. Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24:65-97
34. Jain N, Nguyen H, Chambers C, Kang J (2010) Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 107:1524-1528
35. Johnson GC, Esposito L, Barratt BJ et al (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29:233-237 (Pubitemid 32952665)
36. Anjos SM, Tessier MC, Polychronakos C (2004) Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J Clin Endocrinol Metab 89: 6257-6265 (Pubitemid 39628442)
37. Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA (2003) Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 187:1264-1271 (Pubitemid 36438967)
38. Hou R, Cao B, Chen Z et al (2010) Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 37:515-520
39. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736 (Pubitemid 26102823)
40. Sutmuller RP, van Duivenvoorde LM, van Elsas A et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in anti-tumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832 (Pubitemid 32983017)
41. Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377 (Pubitemid 36842552)
42. Korman A, Yellin M, Keler T (2005) Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6:582-591 (Pubitemid 40852291)